Comparison of supine or prone crawl photon or proton breast and regional lymph node radiation therapy including the internal mammary chain by Speleers, Bruno et al.
1Scientific RepoRts |          (2019) 9:4755  | https://doi.org/10.1038/s41598-019-41283-1
www.nature.com/scientificreports
Comparison of supine or prone 
crawl photon or proton breast and 
regional lymph node radiation 
therapy including the internal 
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Greveling3, Christel M. Monten1,3, Joris J. Van de Velde4, tom H. Vercauteren1,3, 
Liv Veldeman1,3, Damien C. Weber2,6 & Wilfried C. De Neve1,3
We report on a dosimetrical study comparing supine (s) and prone-crawl (p) position for radiotherapy 
of whole breast (WB) and loco-regional lymph node regions, including the internal mammary chain 
(LN_IM). six left sided breast cancer patients were Ct-simulated in s and p positions and four patients 
only in p position. treatment plans were made using non-coplanar volumetric modulated arc photon 
therapy (VMAt) or pencil beam scanning intensity modulated proton therapy (IMpt). Dose prescription 
was 15*2.67 Gy(GyRBE). The average mean heart doses for S or P VMAT were 5.6 or 4.3 Gy, respectively 
(p = 0.16) and 1.02 or 1.08 GyRBE, respectively for IMPT (p = 0.8; p < 0.001 for IMPT versus VMAT). The 
average mean lung doses for S or P VMAT were 5.91 or 2.90 Gy, respectively (p = 0.002) and 1.56 or 1.09 
GyRBe, respectively for IMpt (p = 0.016). In high-risk patients, average (range) thirty-year mortality 
rates from radiotherapy-related cardiac injury and lung cancer were estimated at 6.8(5.4–9.4)% or 
3.8(2.8–5.1)% for S or P VMAT (p < 0.001), respectively, and 1.6(1.1–2.0)% or 1.2(0.8–1.6)% for S or P 
IMpt (p = 0.25), respectively. Radiation-related mortality risk could outweigh the ~8% disease-specific 
survival benefit of WB + LN_IM radiotherapy for s VMAt but not p VMAt. IMpt carries the lowest 
radiation-related mortality risks.
Radiotherapy after breast-conserving surgery improves loco-regional control and survival at the expense of acute 
and late local toxicity, radiation induced cardiac injury, lung cancer and cancer in the non-treated breast, leading 
to dose-dependent excess mortality1–6. Prone radiotherapy allows decreasing dose to lung and heart and thereby 
the risks of radiation-induced lung cancer and cardiac injury7–9. Prone breast radiotherapy devices are typically 
designed to support the patient with both arms elevated. The elevated arm at the treated side and device com-
ponents that support the arm restrict the range of beam directions for whole breast and lymph node irradiation 
(WBI + LNI). Prone WBI + LNI using dorsal beams has been described10. Heart and lung dose from WBI + LNI 
are highest if the internal mammary(IM)-lymphnodes are also irradiated11,12. Long-term mortality risk from 
radiation-induced lung cancer and heart injury increases linearly with mean dose to these organs13. The concern 
that possible benefits from IM-irradiation14 might be offset by radiation-induced heart injury explains reluctance 
of radiation oncologists to treat the IM-nodes.
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We developed a support device for a particular prone position with the patient’s arm alongside the body at 
the treated side and above the head at the contralateral side15, resembling a phase of prone crawl swimming. The 
device, called prone crawl breast couch, allows WBI + LNI using anterior, antero-lateral and para-sagittal beam 
directions without the patient’s arm or device components in the entrance paths of the beams15. We showed that 
prone crawl WBI + LNI (without inclusion of the IM-chain in the lymph node target) reduced heart and lung 
doses as compared to supine techniques16. The purpose of this study was to explore the potential of the prone 
crawl position for organ-at-risk (OAR) sparing in left-sided WBI + LNI (including the IM-chain) using photon 
or proton irradiation.
patients, Materials and Methods
Ten left sided breast cancer patients with invasive carcinoma of the breast and pathologically confirmed positive 
lymph node status were included in this retrospective study. Patients were not selected for large or pendulous 
breasts. All patients underwent lumpectomy and axillary clearance followed by adjuvant WBI + LNI in supine 
position. Written informed consent was obtained before simulation for each patient. The study was conducted 
according to the Declaration of Helsinki and was approved by the ethics board of Ghent University Hospital. 
Six patients were scanned in supine and prone crawl position and 4 patients only in prone crawl position. In 
prone crawl position, patients were positioned on the prone crawl breast couch15,16. The contralateral breast was 
pulled laterally, away from the ipsilateral breast and immobilized using a unilateral bra to increase distance to 
the irradiated area7. In supine position, patients were positioned on the simulator couch using a Posirest arm 
support (Civco Medical Solutions, Kalone, Iowa, United States) with both arms elevated above the head16. For 
both positions, 5 mm slice thickness CT-images were acquired, starting at the vertex and caudally ending below 
the diaphragm.
The target consisted of the breast, the level II-III axillary (AxII-III), inter-pectoral, peri-clavicular (PC) and IM 
lymphnode regions. Delineation was performed on a Pinnacle 9.8 treatment planning system (Philips Healthcare, 
Fitchburg, Wisconsin, United States). In supine position, the contouring guidelines from the ESTRO and PROCAB 
groups17–19 were used to define a clinical target volume for whole breast irradiation (CTV_WBI) and two clinical tar-
get volumes for lymph node irradiation. The whole breast was delineated up to 5 mm from the skin surface as CTV_
WBI. CTV_PC included axillary level II-III, inter-pectoral and peri-clavicular lymph nodes. CTV_MI included 
the IM lymphnodes. As there are no generally accepted guidelines for delineation in prone position, we performed 
delineation of CTV_WBI, CTV_PC and CTV_MI using extrapolation from the guidelines described above.
Planning target volumes PTV_PC and PTV_MI were obtained as 3 mm and 1 mm isotropic expansion of 
CTV_PC and CTV_MI, respectively. PTV_WBI was created using a 5 mm margin except in the medial direction 
to avoid irradiation of the contralateral breast and towards the skin surface to minimize build-up effects. Photon 
plan optimization structures were created to reduce influence of dose buildup underneath the skin on plan opti-
mization and to secure flash.
The heart was delineated according to Feng et al.20. The left anterior descending artery (LAD) and the 
apex were individually delineated. Left and right lungs were contoured separately using the Hounsfield Units 
options provided in Pinnacle³ 9.8 with threshold 800–4096. Contralateral breast was delineated up to the skin. 
Esophagus was delineated, starting cranially from the inferior margin of the cricoid and ending inferiorly at the 
gastro-esophageal margin.
Photon plans used 6 MV X-ray beams which deposit little dose at the skin surface. In the first millimeters 
below the skin surface, the dose deposition rapidly increases. This characteristic, called build-up permits to 
deliver high photon doses at depths more than ~5 mm below the skin without severe skin toxicity. Proton beams 
do not show build-up but techniques like pencil beam scanning can be employed to decrease skin dose. Dose was 
calculated in stacked 1 mm thick layers up to a depth of 5 mm for photon and proton plans. These layers were cre-
ated by the following procedure. The intersection of a 2 cm isotropic expansion of CTV_WBI with a 5 mm thick 
slice immediately below the skin surface was called OAR-skin. The parts of OAR-skin extending 0–1, 1–2, 2–3, 
3–4 and 4–5 mm inside the skin surface defined 5 layers called OAR-skin-d1-d2 where d1 and d2 are depths of 
the superficial and deep surfaces for each of the different layers, respectively. Mean dose in each layer is reported.
Photon plans were created and optimized using planning tools integrated into the GRATIS™ treatment plan-
ning platform (Sherouse systems, Inc., Chapel Hill, NC, USA)21. GRATIS™ and its history is described in the cur-
riculum vitae of George Winthrop Sherouse [http://gwsherouse.com/GWS/cv.pdf]. The tools for VMAT-planning 
that were developed at Ghent University as extensions of the GRATIS™ planning platform are described else-
where22. Plans were made using a supine coplanar or prone non-coplanar multiple overlying partial arc VMAT 
technique to exploit good beam directions and reduce low-dose spread to the organs at risk15,16. The final dose 
calculation was performed using the convolution-superposition dose computation engine in Pinnacle 9.8.
The proton plans were computed on the PSIPlan Treatment Planning System (TPS) for a proton Pencil Beam 
Scanning (PBS) gantry which is a PBS treatment unit with an upstream energy selection design and fast, double 
parallel scanning, with beam widths between 2.5 and 4.5 mm σ in air across the 70–230 MeV available energy23. 
An electronically controlled range-shifter of 4 cm water-equivalent thickness, mounted in the nozzle, can be 
remotely positioned in the beam path, allowing the delivery of Bragg peaks close to the patient surface. The 
range-shifter can be set either ‘in’ or ‘out’ for the delivery of all spots within a single field, or it can be set in ‘auto-
matic mode’, being introduced per single spot when required, i.e. only when the spots need to be located at depths 
<4.3 cm, not reachable with energy >70 MeV.
The proton pencil beams (PBs) are initially placed inside the patient on a rectilinear grid. Then only a 
sub-selection of them covering the target with an isotropic expansion of 5 mm are optimized. Intensity Modulated 
Proton Therapy (IMPT) was used, with simultaneous optimization of all the spots for all the fields24,24. The result-
ing dose distribution is homogenous within the target, but this is obtained by the combination of single field 
non-uniform dose distributions.
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For prone cases 3 oblique fields coming from below the treatment couch were used with about 30° of angular 
spread between them. For the supine cases, one direct anterior and two narrow oblique-lateral fields with about 
20° to 25° of angular spread were used. No couch rotation was applied for any of the cases. The range-shifter was 
set in ‘automatic’ mode for all fields and the drift-space between the exit of the nozzle and the patient’s surface was 
minimized as much as possible so that the beam width of the superficial PBs couldn’t be further deteriorated by 
the multiple coulomb scattering already occurring in the thick range-shifter material.
In order to avoid having to generate individual plans for each of the treated regions, an ad-hoc structure, 
which was a union of individual target volumes, was created in PSIPlan. Each field was calculated on that struc-
ture and finally the weights of the PBs of all fields composing the plan were optimized together so as to achieve 
the most homogeneous dose distribution within it, but no proton PBs were placed in between the individual 
PTVs when they were sufficiently separated (>5 mm) from each other, reducing the amount of healthy tissue 
irradiation. This technique is called ‘Combined Target’ technique. No dose constraints to OARs were needed 
for the dose optimization, except for 2 prone patients for which constraints on the skin, thyroid and esophagus 
were used. The used PBs grid for dose calculation was of 4 mm across the plane transversal to the beam direction 
and 2.5 mm along the beam axis. The final optimized plans were normalized prescribing 100% of the dose to the 
combined PTV.
A median dose of 40.05 Gy(GyRBE) in 15 fractions was prescribed to the optimization structures related to 
PTV_WBI, PTV_PC and PTV_MI. The objective was to have 95% of the volumes covered with at least 95% of the 
prescribed dose (i.e. 38 Gy) and no more than 5% receiving 105% of the prescribed dose (i.e. 42 Gy).
Dose statistics are referred to as Dn (the minimal dose delivered to n % of the volume) or Vn (the volume per-
centage receiving ≥n Gy). D2 and D98 were used as surrogates for maximum and minimum dose, respectively.
Thirty-year mortality risk from radiation-induced cardiac injury and lung cancer was calculated according 
to Taylor et al.13. Cumulative risk of dying from heart disease and/or lung cancer was calculated as 1-(1-Ph)(1-Pl) 
where Ph and Pl are the risks to die from radiation induced heart disease or lung cancer, respectively.
Results
Average breast volume (CTV_WBI) in prone and supine position was 462 (10 patients: range 181–738) cc and 
496 cc (6 patients: range 213–733) cc, respectively.
Figure 1 illustrates differences between prone crawl VMAT and IMPT. These are build-up, dose spread in the 
shoulder and intrathoracic regions at the treated side. Similar dosimetric differences between VMAT and IMPT 
are observed in supine position (not shown).
Dose objectives were met for PTV_WBI, PTV_PC and PTV_MI in all plans. Figure 2 shows no significant dif-
ferences between photon and proton plans regarding the maximum PTV_WBI and PTV_PC doses. For PTV_MI, 
the average dose maximum was about 1 GyRBE higher in supine than in prone crawl proton plans (p = 0.048). 
The minimum dose to the target volumes was higher in proton plans than in photon plans. Comparable maxi-
mum and higher minimum target doses resulted in better dose-homogeneity for proton than for photon plans in 
supine as well as in prone crawl position.
Dose indices of OARs are summarized in Table 1. Mean doses to OARs are lower for prone crawl than for 
supine positions and for proton than for photon plans. The few exemptions are thyroid and esophagus. The lowest 
average mean thyroid dose was obtained in prone crawl photon plans (statistically significant versus all other 
plans). The lowest average mean and D02 esophageal dose was obtained in supine proton and supine photon 
plans, respectively.
Mean dose to the different layers of OAR-skin is shown in Fig. 3. The average mean dose for the most 
superficial layer, OAR-skin-0-1 mm, is 7.7% lower for photon than for proton plans (p < 0.001). The values of 
OAR-skin-0-1 mm underestimate the sparing by photon build-up of the epithelium which is less than 0.2 mm 
thick at the breast. For OAR-skin-1-2mm, the difference is 2.2% (p = 0.018). The build-up of photons cannot be 
distinguished for layers deeper than 2 mm.
Thirty-year risk estimates of dying from radiation induced heart disease or lung cancer for a 50-year old ref-
erence patient are given in Table 2.
Discussion
The absolute 15-year disease-specific mortality reduction by adjuvant radiotherapy was estimated to be 3.8% in 
patients receiving radiotherapy after breast-conserving surgery, the majority being node-negative26. Absolute 
20-year disease-specific mortality was reduced ~8% after mastectomy and radiotherapy in node-positive 
patients27. Non-randomized evidence exists that disease-specific mortality reduction could be equal28 or even 
larger14,29 if the IM-nodes are also treated. After adjuvant radiotherapy, the lower overall than disease-specific 
survival rates can be partially explained by mortality from radiation-induced cardiac disease and secondary can-
cer, mainly lung cancer. In patient groups with risk factors for developing cardiac disease or lung cancer, adjuvant 
radiotherapy may even be detrimental13. The excess mortality risk increases with mean dose to heart and lungs 
with no threshold5,13. These insights are the rationale behind research exploring techniques to decrease dose to 
OARs and cast doubt on the use of planning OAR-constraints below which no further effort would be needed. 
Techniques include prone positioning, deep-inspiration breath hold (DIBH), non-coplanar beam directions, 
short-arc VMAT, narrow PTV-margins in combination with IGRT and proton therapy. Prone crawl position 
offers the possibility to use several techniques simultaneously in patients requiring breast and lymph node irra-
diation. This study focused on breast and lymph node irradiation including the IM-nodes because these patients 
receive the highest OAR-doses11 and because recent publications may lead to more IM irradiation14,29. The nov-
elties investigated in this study are i) use of non-coplanar VMAT using arc directions that were made possible 
by a prone crawl breast couch15 (ii) comparison between supine and prone position for photon WBI + LNI (with 
IM-nodes); (iii) comparison between photon and proton radiotherapy for both patient set-ups.
4Scientific RepoRts |          (2019) 9:4755  | https://doi.org/10.1038/s41598-019-41283-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
Coverage of the breast and nodal targets was equally achieved in supine and in prone crawl position. However, 
the minimum dose in proton plans was higher for all targets, leading to better dose homogeneity than in photon 
plans in supine as well as in prone crawl positions. The lower minimum dose in photon plans cannot be explained 
by photon build-up as this affects only the most superficial 2 mm whereas dose is reported for target volumes after 
exclusion of the most superficial 5 mm.
Dose indices that have been related to cardiac injury and mortality (mean and maximum doses to the heart, 
LAD and apex) were generally lower for prone crawl than for supine positions and lower for proton than for 
photon plans. A drawback of this study is the absence of CT-simulation images in DIBH for supine and/or prone 
positions. In the period 2003–2013, mean heart doses from loco-regional irradiation including the IM-chain, 
were estimated to be around 2.5 GyRBE using protons and around 8 Gy or 4 Gy using photons without or with 
breathing control, respectively11. Mean heart dose in prone crawl position without breathing control (4.3 Gy 
(3.0–5.6)) is similar to the values reported with breathing control11 and is about half of the 8.7 Gy mean heart 
dose reported for left-side prone tomotherapy plans by Kainz30. Using DIBH in prone crawl position we achieved 
mean heart doses below 2.5 Gy for all patients who were treated at the left IM-chain using photons (unpublished 
data). However, 8–12 DIBHs of 15–25 seconds were required to complete a non-coplanar VMAT treatment. Not 
all patients are capable of such repeated DIBH maneuvers. Prolonged DIBH or jet-ventilation techniques31,32 are 
evaluated. In proton plans, mean heart doses were less than 2 GyRBE in all patients. As compared to photons, 
proton plans showed 3–5-fold reduction of mean heart, LAD and apex doses.
Risk estimates for radiation-induced cardiac mortality (Table 2) show rates <0.5–0.1% in patients without 
cardiac risk factors, which can be considered low when compared to the disease-specific survival gain of ~8% 
for loco-regional adjuvant radiotherapy. In patients with cardiac risk factors, radiation-related cardiac mor-
tality would affect >1% of patients treated with photons and many more would be at risk of suffering from 
radiation-related non-fatal cardiac events during follow-up. According to Smolina et al.33, the death risk rate 
(myocardial infarction/death from myocardial infarction) is around 5 in women <75 years of age (case-fatality 
rate = 0.19 in 2010). Using a death risk rate of 5, more than 6% of high-risk patients would suffer from major 
cardiac event(s) during 30-year follow-up after photon treatment.
The main advantage of prone radiotherapy is lowering lung dose. Risk estimations for radiation-induced lung 
cancer mortality (Table 2) show rates <0.4–0.1% in patients who did never smoke. In a patient 50 years old at 
diagnosis, who smoked since adolescence and continued smoking, 30-year radiation-related lung cancer mortal-
ity would be more than 5% when treated with photons in supine position and around 2.5% when treated in prone 
crawl position. Proton therapy reduces lung cancer mortality risk to less than 1.5% and 1% in supine or prone 
crawl position, respectively.
Figure 1. Transverse and sagittal dose distributions of prone photon (left) and proton (right) plans. The main 
difference is larger dose spread outside the target volumes in VMAT than in IMPT plans. Larger dose spread 
is seen in de dorsal shoulder region (indicated by the red number (1) and inside the thorax (indicated by the 
yellow number (2).
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Patients who are high-risk for lung cancer may simultaneously be high-risk for cardiac events by 
tobacco-related or other factors of cardiac disease. Figure 4, a plot of mean lung and heart doses for each patient 
shows that the combined mortality risk would outweigh a 30-year disease-specific survival benefit of 8% in 2/6 
patients using supine photon plans but not using prone crawl photon or proton plans. Risk calculations based on 
cardiac and lung cancer mortality neglect risk-contributions from other radiation-induced cancers, such as eso-
phageal, thyroid or contralateral breast cancer. Hence, radiation-related mortality risk is underestimated. Taylor’s 
data11 are based on a variety of prescription doses, the most common being 25*2.0 Gy. The prescription dose in 
this study was 15*2.67 Gy. A weakness of these risk calculations is that neither total dose nor fractionation could 
be taken into account.
Figure 2. Maximum (D02) and minimum (D98) dose in breast and lymph node targets. Dose range: 34–46 Gy/
GyRBE. P1–P6: patients (n = 6) for whom CT-simulation was performed in supine and prone crawl positions. 
Paired t-tests.
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Dose calculation algorithms might bias the comparison between photon and proton plans. Stray radiation was 
calculated in photon plans but not in proton plans. In proton PBS, stray radiation consists mainly of fast neutrons 
generated in the tissues of the patient and in the 4 cm thick range shifter of the nozzle used to generate superficial 
Dose (Gy(RBE))
Photon Proton Ph/Pr sup Ph/Pr pro
supine prone crawl p-value supine prone crawl p-value p-value p-value
Heart (mean) 5.6 (3.5–8.8) 4.3 (3.0–5.6) 0.16 1.02 (0.6–1.6) 1.08 (0.6–1.9) 0.8 <0.001 <0.001
LAD (mean) 21.4 (14.8–26.7) 9.0 (4.1–15.8) <0.001 3.4 (0.7–11.6) 2.0 (0.02–10.9) <0.001 <0.001 <0.001
Heart apex (mean) 15.6 (10.2–29.4) 13.3 (4.1–25.3) 0.54 4.3 (0.11–13.0) 5.3 (0.04–16.4) 0.72 0.002 <0.001
Lungs (mean) 5.91 (4.1–7.8) 2.90 (2.1–3.9) 0.002 1.56 (1.1–2.0) 1.09 (0.7–1.7) 0.016 <0.001 <0.001
Lung ipsilateral (mean) 11.54 (9.1–15.7) 5.3 (4.0–6.5) <0.001 3.5 (2.5–4.3) 2.4 (1.6–3.4) <0.001 <0.001 0.007
Lung contralateral (mean) 1.6 (0.73–5.4) 0.91 (0.39–1.8) 0.4 0.12 (0.02–0.25) 0.04 (0.02–0.06) 0.15 0.1 <0.001
Thyroid (mean) 11.61 (4.1–21.3) 3.31 (0.8–6.2) 0.019 7.18 (2.8–10.5) 6.32 (1.1–11.0) 0.6 0.04 0.01
Esophagus (mean) 2.8 (1.8–6.3) 2.5 (1.1–4.6) 0.71 1.4 (0.2–2.8) 2.2 (0.6–5.1) 0.21 0.11 0.5
Esophagus (D02) 11.8 (3.6–26.4) 14.9 (2.8–34.5) 0.52 14.7 (3.2–27.7) 20.5 (7.2–35.7) 0.23 0.43 0.005
Esophagus (D02<20 Gy(RBE)) 5/6 patients 9/10 patients 4/6 patients 5/10 patients
R breast (mean) 2.0 (0.8–4.6) 0.7 (0.2–1.1) 0.07 0.03 (0.02–0.05) 0.04 (0.02–0.07) 0.15 0.01 <0.001
R breast (mean < 1 Gy(RBE)) 1/6 patients 8/10 patients 6/6 patients 10/10 patients
Table 1. Dose indices for organs-at-risk. Average values (range) for 6 or 10 patients. Column 4: p-values for 
photon supine versus photon prone crawl plans (unpaired t-test). Column 7: p-values for proton supine versus 
proton prone crawl plans (unpaired t-test). Column 8: p-values for supine versus prone crawl photon plans 
(paired t-test). Column 9: p-values for supine versus prone crawl proton plans (paired t-test).
Figure 3. Skin dose. Dose range: 0–40 Gy/GyRBE for patients 1–6. Color lines drawn on the CT-scan image 
represent the different layers OAR-skin-0–1mm to OAR-skin-4–5mm. Data points are mean dose to these 
structures.
Figure 4. Risk-benefit classification of high-risk patients for cardiac events and lung cancer. Data points 
represent mean heart and mean lung doses of individual patients treated supine or prone crawl using photons 
or protons. Line of regret 8%: data points on the line represent 8% absolute 30-year survival loss from combined 
radiotherapy-related cardiac and lung cancer mortality.
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Bragg peaks. Integral dose from neutron radiation using proton PBS is much lower than stray radiation (mainly 
phantom scatter) using photons34. We observed good accuracy of Pinnacle convolution-superposition dose calcu-
lation algorithm in the build-up region for VMAT plans of whole brain radiotherapy35. We assumed that similar 
accuracy was obtained in VMAT for breast and lymph node radiotherapy.
Except for skin, the lowest doses to OAR are obtained by proton therapy in supine or prone crawl position. The 
drawbacks of proton therapy for adjuvant breast cancer treatment are increased skin toxicity, cost and availability. 
Using constraints to skin, PBS optimization could reduce dose in the most superficial 5 mm to 90–95% of the 
WBI prescription dose but cannot reach the level of under-dosage offered by megavoltage photon beams at the 
depth of the germinative layer of the skin epithelium which is 0.1–0.2 mm below the surface at the treated breast.
Conclusion
Target coverage was better for proton than for photon plans and equally good in supine as in prone crawl posi-
tion plans for each radiation modality. Mean doses to organs-at-risk are generally lower for prone crawl than for 
supine positions and for proton than for photon plans. Survival benefit/risk ratio <1 occurred for supine photon 
plans. Proton plans showed the lowest radiation-related mortality risks.
Data Availability
The datasets generated during and/or analyzed during the current study are not publicly available due to patient 
privacy rights but are available in an anonymized form from the corresponding author on reasonable request.
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WBI + LNI + MI
Photon VMAT Proton IMPT
Supine Prone-crawl Supine Prone-crawl
Heart_mean dose (Gy(RBE)) 5.6 4.34 1.02 1.08
No cardiac risk factor-no smoking
ΔRisk cardiac death (0.075%/Gy(RBE)) 0.42 0.3255 0.0765 0.081
ΔRisk cardiac death (1/N) 238 307 1307 1234
Cardiac risk factor(s) or smoking
ΔRisk cardiac death (0.3%/Gy(RBE)) 1.68 1.302 0.306 0.324
ΔRisk cardiac death (1/N) 59 76 326 308
Lungs_mean dose (Gy(RBE)) 5.91 2.9 1.56 1.09
No smoking
ΔRisk lung cancer death (0.06%/Gy(RBE)) 0.3546 0.174 0.0936 0.0654
ΔRisk lung cancer death (1/N) 282 574 1068 1529
Continuing smoking
ΔRisk lung cancer death (0.88%/Gy(RBE)) 5.2008 2.552 1.3728 0.9592
ΔRisk lung cancer death (1/N) 19 39 72 104
Heart disease*lung cancer mortality
In high-risk patients: 1 - ∏(1-p)(%) 6.8 3.8 1.6 1.2
~8% benefit
Table 2. Risk estimations for radiation-induced mortality. Risk estimations for radiation-induced mortality, 
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